Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Prasad, V. K., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 503 · see citing works

Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database

Majhail, N. S., Mau, L., Denzen, E. M., & Arneson, T. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.133 · Cited by 143 · see citing works

Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?

Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 139 · see citing works

Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?

Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 112 · see citing works

FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome

Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm574154.htm · Cited by 28 · see citing works

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 801 · see citing works

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions

Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 726 · see citing works

Enabling Technologies for Personalized and Precision Medicine

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517 · see citing works

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478 · see citing works

Engineering microrobots for targeted cancer therapies from a medical perspective

Schmidt, C. K., Medina‐Sánchez, M., Edmondson, R. J., & Schmidt, O. G. (2020) · Nature Communications · doi:10.1038/s41467-020-19322-7 · Cited by 447 · see citing works

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, C., Wang, Z.-L., Xu, T., He, Z., & Wei, Y.-Q. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 331 · see citing works

Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy

Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310 · see citing works

Biomaterials tools to modulate the tumour microenvironment in immunotherapy

Chao, Y., & Liu, Z. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00004-6 · Cited by 262 · see citing works

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Mahadeo, K. M., Khazal, S. J., Abdel‐Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D. C., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0075-2 · Cited by 240 · see citing works

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 241 · see citing works

Organ-on-a-Chip for Cancer and Immune Organs Modeling

Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221 · see citing works

Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 208 · see citing works

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

Dejenie, T. A., Medhin, M. T. G., Terefe, G. D., Admasu, F. T., Tesega, W. W., & Abebe, E. C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 191 · see citing works

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies

Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., & Paulos, C. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01740 · Cited by 186 · see citing works

Nanobody-based CAR-T cells for cancer immunotherapy

Kozani, P. S., Naseri, A., Mirarefin, S. M. J., Salem, F., Nikbakht, M., Bakhshi, S. E., & Kozani, P. S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00371-7 · Cited by 185 · see citing works

CRISPR–Cas: a tool for cancer research and therapeutics

Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 178 · see citing works

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study

Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 159 · see citing works

A new era of cancer phototherapy: mechanisms and applications

Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 157 · see citing works

CAR-NK Cells: From Natural Basis to Design for Kill

Khawar, M. B., & Sun, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707542 · Cited by 155 · see citing works

Biological Products: Cellular Therapy and FDA Approved Products

Golchin, A., & Farahany, T. Z. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9866-1 · Cited by 148 · see citing works

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

Cliff, E. R. S., Kelkar, A. H., Russler‐Germain, D. A., Tessema, F. A., Raymakers, A., Feldman, W. B., & Kesselheim, A. S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397912 · Cited by 137 · see citing works

Synthetic gene circuits for the detection, elimination and prevention of disease

Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0215-0 · Cited by 136 · see citing works

Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments

Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134 · see citing works

Harnessing the chemokine system to home CAR-T cells into solid tumors

Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 127 · see citing works

Vascular Microenvironment, Tumor Immunity and Immunotherapy

Lamplugh, Z. L., & Fan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811485 · Cited by 126 · see citing works

Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy

Yang, Y. P., Sun, X., Xu, J., Cui, C., Yazd, H. S., Pan, X., Zhu, Y., Chen, X., Li, X., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09884 · Cited by 113 · see citing works

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

Vairy, S., Garcia, J. L., Teira, P., & Bittencourt, H. N. D. S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s138765 · Cited by 112 · see citing works

Cost of decentralized CAR T‐cell production in an academic nonprofit setting

Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 113 · see citing works

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Xin, T., Li, C., Zhou, C., Zhao, Y., Hu, Z., & Wu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809754 · Cited by 110 · see citing works

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?

Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 110 · see citing works

Imaging of tumour response to immunotherapy

Dromain, C., Beigelman‐Aubry, C., Pozzessere, C., Durán, R., & Digklia, A. (2020) · European Radiology Experimental · doi:10.1186/s41747-019-0134-1 · Cited by 98 · see citing works

Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways

Yang, Y., Badeti, S., Hsiang-Chi, T., Ma, M. T., Liu, T., Jiang, J., Liu, C., & Liu, D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.014 · Cited by 94 · see citing works

Engineering chimeric antigen receptor-T cells for cancer treatment

Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95 · see citing works

Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy

Han, J., Lim, J., Wang, C. J., Han, J., Shin, H. E., Kim, S.-N., Jeong, D., Lee, S. H., Chun, B.-H., Park, C. G., et al. (2023) · Nano Convergence · doi:10.1186/s40580-023-00385-3 · Cited by 94 · see citing works

Engineering Precision Medicine

Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 93 · see citing works

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods

Harrison, R. P., Zylberberg, E., Ellison, S., & Levine, B. L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.01.003 · Cited by 90 · see citing works

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Qu, T., Li, B., & Wang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00373-5 · Cited by 90 · see citing works

Materials for Improving Immune Cell Transfection

Kumar, A. R. K., Shou, Y., Chan, B., Krishaa, L., & Tay, A. K. P. (2021) · Advanced Materials · doi:10.1002/adma.202007421 · Cited by 82 · see citing works

RNA delivery biomaterials for the treatment of genetic and rare diseases

Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing

Liu, J., Zhou, G., Li, Z., & Zhao, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00456 · Cited by 81 · see citing works

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity

Li, Y.-R., Brown, J., Yu, Y., Lee, D. P. H., Zhou, K., Dunn, Z. S., Hon, R., Wilson, M., Kramer, A. B., Zhu, Y., et al. (2022) · Cancers · doi:10.3390/cancers14112749 · Cited by 78 · see citing works

A Single-Step Chemoenzymatic Reaction for the Construction of Antibody–Cell Conjugates

Li, J., Chen, M., Liu, Z., Zhang, L., Felding, B. H., Moremen, K. W., Lauvau, G. S., Abadier, M., Ley, K. F., & Wu, P. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00552 · Cited by 77 · see citing works

Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models

Volpe, A., Lang, C., Lim, L., Man, F., Kurtys, E., Ashmore‐Harris, C., Johnson, P., Skourti, E., de Rosales, R. T. M., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.028 · Cited by 78 · see citing works

Next-generation drug repurposing using human genetics and network biology

Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 76 · see citing works

Antibody variable region engineering for improving cancer immunotherapy

Lou, H., & Cao, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12330 · Cited by 75 · see citing works

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 73 · see citing works

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 75 · see citing works

Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities

Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 71 · see citing works

Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70 · see citing works

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer

Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67 · see citing works

Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality

Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68 · see citing works

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 65 · see citing works

CAR T-cells: costs, comparisons, and commentary

Hay, A. E., & Cheung, M. C. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1582059 · Cited by 66 · see citing works

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 64 · see citing works

Materials for Cell Surface Engineering

Adebowale, K., Liao, R., Suja, V. C., Kapate, N., Lu, A., Gao, Y., & Mitragotri, S. (2023) · Advanced Materials · doi:10.1002/adma.202210059 · Cited by 64 · see citing works

In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes

Naghizadeh, A., Tsao, W.-C., Cho, J. H., Xu, H., Mohamed, M., Li, D., Xiong, W., Metaxas, D., Ramos, C. A., & Liu, D. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009883 · Cited by 60 · see citing works

Tumor response assessment on imaging following immunotherapy

Berz, A. M., Dromain, C., Violi, N. V., Boughdad, S., & Durán, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982983 · Cited by 60 · see citing works

Design of a Peptide-Based Electronegative Hydrogel for the Direct Encapsulation, 3D Culturing, in Vivo Syringe-Based Delivery, and Long-Term Tissue Engraftment of Cells

Yamada, Y., Patel, N. L., Kalen, J. D., & Schneider, J. P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12152 · Cited by 60 · see citing works

Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages

Li, X., Guo, X., Ling, J., Tang, Z., Huang, G., He, L., & Chen, T. (2021) · Nanoscale · doi:10.1039/d0nr08050k · Cited by 58 · see citing works

Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics

Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 59 · see citing works

Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery

Falcone, N., Ermis, M., Tamay, D. G., Mecwan, M. M., Monirizad, M., Mathes, T. G., Jucaud, V., Choroomi, A., de Barros, N. R., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301096 · Cited by 58 · see citing works

Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada

Furzer, J., Gupta, S., Nathan, P. C., Schechter, T., Pole, J. D., Krueger, J., & Pechlivanoglou, P. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5909 · Cited by 56 · see citing works

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 57 · see citing works

Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches

Zheng, Y., Nandakumar, K. S., & Cheng, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02054 · Cited by 54 · see citing works

The CD47-SIRPα axis is a promising target for cancer immunotherapies

Hao, Y., Zhou, X., Li, Y., Li, B., & Lei, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110255 · Cited by 53 · see citing works

Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 53 · see citing works

Redox Electrochemistry to Interrogate and Control Biomolecular Communication

VanArsdale, E. S., Pitzer, J., Payne, G. F., & Bentley, W. E. (2020) · iScience · doi:10.1016/j.isci.2020.101545 · Cited by 53 · see citing works

Peptide Delivery Systems for Cancer Vaccines

He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 45 · see citing works

T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

Lin, Y., & Wang, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02867-6 · Cited by 43 · see citing works

A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19

Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42 · see citing works

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

Nasiri, F., Kozani, P. S., & Rahbarizadeh, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063838 · Cited by 42 · see citing works

Novel antigens of CAR T cell therapy: New roads; old destination

Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101079 · Cited by 43 · see citing works

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

Truong, N. T., Gargett, T., Brown, M. P., & Ebert, L. M. (2021) · Cancers · doi:10.3390/cancers13092225 · Cited by 45 · see citing works

Immunotherapy approaches for the treatment of diffuse midline gliomas

Bernstock, J. D., Hoffman, S. E., Kappel, A. D., Valdes, P. A., Essayed, W. I., Klinger, N. V., Kang, K., Totsch, S. K., Olsen, H. E., Schlappi, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124058 · Cited by 41 · see citing works

Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse

Liu, L., Ma, C., Zhang, Z., Witkowski, M. T., Aifantis, I., Ghassemi, S., & Chen, W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005360 · Cited by 40 · see citing works

The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies

Fruhwirth, G. O., Kneilling, M., de Vries, I. J. M., Weigelin, B., Srinivas, M., & Aarntzen, E. H. J. G. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1254-3 · Cited by 40 · see citing works

Sniping Cancer Stem Cells with Nanomaterials

Wang, W.-D., Guo, Y., Yang, Z., Su, G.-L., & Sun, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c07828 · Cited by 38 · see citing works

Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies

Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39 · see citing works

Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies

Weisbrod, L. J., Anand, T., Vengoji, R., Shonka, N., Jain, M., Ho, W. S., Batra, S. K., & Salehi, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216876 · Cited by 42 · see citing works

Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics

Scheller, J., Engelowski, E., Moll, J. M., & Floss, D. M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.001 · Cited by 37 · see citing works

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

Ren, L., Leisegang, M., Deng, B., Matsuda, T., Kiyotani, K., Kato, T., Harada, M., Park, J., Saloura, V., Seiwert, T. Y., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568813 · Cited by 36 · see citing works

Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?

Jiang, H., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00247-8 · Cited by 37 · see citing works

mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells

Jayasooriya, V., Ringwelski, B., Dorsam, G. P., & Nawarathna, D. (2021) · Lab on a Chip · doi:10.1039/d1lc00219h · Cited by 34 · see citing works

Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies

Cherian, S., & Stetler‐Stevenson, M. (2018) · Current Protocols in Cytometry · doi:10.1002/cpcy.44 · Cited by 34 · see citing works

Immunotherapies and immunomodulatory approaches in clinical trials - a mini review

Yatoo, M. I., Hamid, Z., RATHER, I. A., Nazir, Q. U. A., Bhat, R. A., Haq, A. U., Magray, S. N., Haq, Z. U., Sah, R., Tiwari, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1871295 · Cited by 34 · see citing works

Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward

Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765097 · Cited by 35 · see citing works

Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas

Noon, A., & Galbán, S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100899 · Cited by 36 · see citing works

Scaffold‐Mediated Static Transduction of T Cells for CAR‐T Cell Therapy

Agarwalla, P., Ogunnaike, E. A., Ahn, S., Ligler, F. S., Dotti, G., & Brudno, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000275 · Cited by 32 · see citing works

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells

Dwivedi, A., Karulkar, A., Ghosh, S., Srinivasan, S., Kumbhar, B. V., Jaiswal, A. K., Kizhakeyil, A., Asija, S., Rafiq, A., Kumar, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0476 · Cited by 33 · see citing works

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis

Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2276 · Cited by 31 · see citing works

Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer

Chu, W., Zhou, Y., Tang, Q., Wang, M., Ji, Y., Yan, J., Yin, D., Zhang, S., Lu, H., & Shen, J. (2018) · BioScience Trends · doi:10.5582/bst.2018.01048 · Cited by 31 · see citing works

A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9

Saber, M. A., Biswas, P., Dey, D., Kaium, M. A., Islam, M. A., Tripty, M. I. A., Rahman, M. H., Rahaman, T. I., Biswas, M. Y., Paul, P., et al. (2021) · Processes · doi:10.3390/pr10010016 · Cited by 35 · see citing works

Prediction of Gold Nanoparticle and Microwave-Induced Hyperthermia Effects on Tumor Control via a Simulation Approach

Dimitriou, N. M., Pavlopoulou, A., Tremi, I., Kouloulias, V., Tsigaridas, G., & Georgakilas, A. G. (2019) · Nanomaterials · doi:10.3390/nano9020167 · Cited by 30 · see citing works

Nucleic Acid Immunotherapeutics for Cancer

Shen, T., Zhang, Y., Zhou, S., Lin, S., Zhang, X., & Zhu, G. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00101 · Cited by 31 · see citing works

Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments

Nix, M. A., & Wiita, A. P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.02.024 · Cited by 29 · see citing works

The biology and therapeutic management of melanoma brain metastases

Abate‐Daga, D., Ramello, M. C., Smalley, I., Forsyth, P. A., & Smalley, K. S. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.019 · Cited by 30 · see citing works

A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration

Santiago, C. P., Keuthan, C. J., Boye, S. L., Boye, S. L., Imam, A. A., & Ash, J. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.016 · Cited by 29 · see citing works

FDA Approval of Tisagenlecleucel

Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017) · JAMA · doi:10.1001/jama.2017.15218 · Cited by 168 · see citing works

Value and affordability of CAR T-cell therapy in the United States

Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 146 · see citing works

Improving outcomes and mitigating costs associated with CAR T-cell therapy

Rebecca Borgert, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88737 · Cited by 87 · see citing works

The Value of CAR-T-cell Immunotherapy in Cancer

Abou‐El‐Enein, M., & Gauthier, J. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_46 · Cited by 10 · see citing works

How Should We Determine the Value of CAR T-Cell Therapy?

Silbert, S. K., Yanik, G. A., & Shuman, A. G. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.844 · Cited by 20 · see citing works